Skip to main content

Nuclear expression of S‐phase kinase–associated protein 2 predicts poor prognosis of hepatocellular carcinoma

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Shin E, Kim S‐H, Jeong H‐Y, Jang J‐J, Lee K. Nuclear expression of S‐phase kinase–associated protein 2 predicts poor prognosis of hepatocellular carcinoma. APMIS 2012; 120: 349–57.

The S‐phase kinase–associated protein 2 (Skp2), which ubiquitinates the cell cycle inhibitor p27Kip1 and targets it for degradation, is commonly overexpressed in human cancers and is associated with poor prognosis in several cancers. The aim of this study was to investigate Skp2 expression and its clinicopathologic significance in surgically resected hepatocellular carcinomas. We collected 359 hepatocellular carcinoma samples and evaluated Skp2 protein expression in cytoplasmic and nuclear fractions by immunohistochemistry using a tissue microarray method. Among the 359 patients, nuclear expression of Skp2 was observed in 41 (10.38%), and cytoplasmic expression of Skp2 was observed in 195 (49.37%). Of the several clinicopathologic variables examined, high Edmonson‐Steiner grade and early recurrence correlated with nuclear expression of Skp2 (p = 0.000 and 0.022, respectively). Cytoplasmic expression of Skp2 correlated negatively with microvascular and macrovascular invasion, tumor size, histologic grade, and overall survival. Multivariate analysis revealed that nuclear expression of Skp2 correlated with short disease‐free survival. Our findings suggest that nuclear expression of Skp2 may be used as an independent predictor of poor prognosis for hepatocellular carcinoma, whereas cytoplasmic expression of Skp2 may indicate less aggressive disease.

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1600-0463.2011.02838.x

Affiliations: Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

Publication date: 2012-05-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more